Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29771040 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9KMT2ABTKJAK2 | |
| SCHEMBL29771165 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9KMT2ABTKJAK2 | |
| SCHEMBL20330486 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9KMT2ABTKJAK2 | |
| SCHEMBL20299315 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9KMT2ABTKJAK2 | |
| SCHEMBL29501906 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9KMT2ABTKJAK2 | |
| SCHEMBL29501867 | 0.93 | MAPK8 (0.43) | MAPK8MAPK9KMT2ABTKMAPK1 | |
| SCHEMBL21593678 | 0.93 | MAPK8 (0.43) | MAPK8MAPK9KMT2ABTKMAPK1 | |
| SCHEMBL21591892 | 0.93 | MAPK8 (0.43) | MAPK8MAPK9KMT2ABTKMAPK1 | |
| SCHEMBL20299476 | 0.93 | MAPK8 (0.43) | MAPK8MAPK9KMT2ABTKMAPK1 | |
| Fluoride SCHEMBL13518132 | 0.87 | KMT2A (0.57) | MAPK8KMT2AJAK2SYKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2024-04-18 | — | — | US | disclosed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-09-05 | — | — | US | disclosed |
| EP-3807278-B1 | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-08-31 | — | — | EP | disclosed |
| CN-110177791-B | Amino-triazolopyridine compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2021-10-05 | — | — | US | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | disclosed |
| EP-3558997-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2019-10-30 | — | — | EP | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114999-A1 | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124492-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885KMT2A 648/4885 |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | RECQL, PRPS1, PURB | MAPK8 1897/4885MAPK9 1136/4885KMT2A 1645/4885 |
| US-11136340-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885KMT2A 648/4885 |
| US-20180194782-A1 | Amino-triazolopyridine Compounds and Their Use in Treating Cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885KMT2A 648/4885 |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | RECQL, PRPS1, PURB | MAPK8 2159/4885MAPK9 1317/4885KMT2A 1635/4885 |
| US-11746118-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885KMT2A 648/4885 |
| US-10407446-B2 | Amino-triazolopyridine compounds and their use in treating cancer | DCK, TYMP, DPYD | MAPK8 989/4885MAPK9 471/4885KMT2A 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.